论文部分内容阅读
吸入性糖皮质激素是治疗慢性阻塞性肺疾病的常规用药,具有显著的抗炎作用,对慢性阻塞性肺疾病患者的临床症状具有明显的改善作用。但吸入性糖皮质激素的副作用也同样困扰着慢性阻塞性肺疾病患者。张伟教授从西药中化的角度,以慢性阻塞性肺疾病的病因病机和近年来对糖皮质激素的中药药性研究成果为依据,结合自己多年的临床经验,创新性地对吸入性糖皮质激素予以中药配伍的形式,以达到减毒增效的目的,弥补了吸入性糖皮质激素的不足。
Inhaled glucocorticoid is a common drug for the treatment of chronic obstructive pulmonary disease, has a significant anti-inflammatory effect, and has obvious improvement on the clinical symptoms of patients with chronic obstructive pulmonary disease. But the side effects of inhaled glucocorticoids also plague patients with chronic obstructive pulmonary disease. Professor Zhang Wei from the perspective of western medicine to chronic obstructive pulmonary disease etiology and pathogenesis and in recent years on the Chinese medicine glucocorticoid research results, combined with their many years of clinical experience, innovative inhalation of the glucocorticoid Hormones in the form of compatibility of traditional Chinese medicine, in order to achieve the purpose of attenuated and synergistic to make up for the lack of inhaled corticosteroids.